News

Helius Medical Technologies (HSDT)(HSM:CA) – Andreeff Appointed Full-time CEO, Names New CFO

Health
0 min read

Thursday, June 17, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
Andreeff Appointed Full-time CEO, Names New CFO

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Kevin Wahle, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Permanent CEO. Helius has named interim CEO and President Dane Andreeff as full-time CEO and President. Mr. Andreeff was appointed to the interim roles in August 2020. Since assuming the roles, Mr. Andreeff guided Helius to FDA approval of the PoNS treatment for MS in the U.S. and is positioning the Company to capitalize on its key technology. Mr. Andreeff remains a significant owner of Helius with approximately 5% of the outstanding shares through his Maple Leaf Partners fund.

    New CFO.  In addition, the Board appointed Jeffrey Mathiesen as CFO. Mr. Mathiesen served as a member of Helius’ Board from June 2020 until June 2021. A CPA with over 30 years experience, Mr. Mathiesen brings a solid background as CFO for a number of growth oriented, technology-based companies across a wide range of industries, including biopharmaceutical and medical device companies …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.